<p>STERIS NYSE: STE 的高管在公司财报电话会议上强调了 2026 财年第三季度的广泛增长、改善的盈利能力以及持续的关税压力，同时维持了全年指引，并指出第四季度的比较将更加具有挑战性。</p>
<h2>第三季度业绩：收入增长 9%，每股收益增长 9%</h2>
<p>首席财务官 Karen Burton 表示，第三季度来自持续运营的收入按报告基准增长了 9%。在固定汇率下，按需收入增长了 8%，主要受销量和约 200 个基点的价格推动。</p>
<p>盈利能力受到关税和通货膨胀的压力。毛利率同比下降 70 个基点至 43.9%，Burton 指出，积极的价格和生产力收益被增加的关税和通货膨胀 “完全抵消”。息税前利润（EBIT）率下降了 40 个基点，降至收入的 22.9%，她表示这主要是由于毛利率降低，部分通过运营费用的控制得以缓解。</p>
<p>调整后的有效税率为 24.2%，较去年同期的 24.5% 略有下降，主要由于地理组合的变化。来自持续运营的调整后净收入为 2.494 亿美元，稀释后每股收益为 2.53 美元，同比增长 9%。</p>
<h2>现金流、债务和资本支出</h2>
<p>Burton 表示，2026 财年前九个月的资本支出总计为 2.788 亿美元，而折旧和摊销总计为 3.631 亿美元。STERIS 在本季度结束时的总债务为 19 亿美元，毛债务与息税折旧摊销前利润（EBITDA）比率约为 1.2 倍。</p>
<p>2026 财年前九个月的自由现金流为 7.366 亿美元，同比改善，主要由于盈利能力提高和资本支出减少。在问答环节中，管理层表示对全年自由现金流目标保持信心，但提到第四季度的时机因素——特别是 “重资本季度”——可能会将现金回收推迟到明年。Burton 还指出，冬季天气可能会影响时机，导致对指引采取保守态度。</p>
<h2>细分市场表现：医疗保健、AST 和生命科学</h2>
<p>总裁兼首席执行官 Dan Carestio 表示，公司医疗保健部门在本季度实现了 8% 的固定汇率有机收入增长，所有类别均有 “增长”。服务收入继续表现优异，增长 11%，而消耗品增长 8%，资本设备增长 7%。医疗保健资本积压保持在 4 亿美元以上。Carestio 表示，订单同比下降 1%，与去年强劲的业绩相比 “比较困难”。</p>
<p>医疗保健的 EBIT 率下降了 100 个基点，降至 24.3%。Carestio 将利润率下降归因于关税和通货膨胀，这些因素超过了销量、定价和重组计划带来的收益。</p>
<p>在应用灭菌技术（AST）方面，固定汇率有机收入增长了 8%，其中服务增长 9%，资本设备收入增长 103%。Carestio 表示，AST 服务受益于稳定的医疗设备销量、生物处理需求和汇率。AST 的 EBIT 率为 45.1%，同比上升 30 个基点，因为定价和销量超过了更高的劳动力和能源成本以及强劲资本设备增长带来的不利组合影响。</p>
<p>在生命科学领域，固定汇率有机收入增长了 5%，主要受 11% 消耗品增长的推动。资本设备收入增长了 7%，积压保持在 1 亿美元以上。细分市场利润率下降了 20 个基点，因为销量和价格的增长被关税和通货膨胀所抵消。</p>
<h2>关税：影响和缓解措施</h2>
<p>Carestio 表示，第三季度的业绩包括约 1600 万美元的税前关税影响，主要集中在医疗保健部门。管理层表示，预计第四季度的关税成本将增加。</p>
<p>在问答环节中，高管们澄清了指引中提到的 5500 万美元关税数字反映的是 2026 财年的年化运行率，并且每个季度都产生了关税。公司还表示，全年展望中预期的关税增加了 1000 万美元，Carestio 表示这使得每股收益指引范围的上限 “变得不太可能”。</p>
<p>管理层描述了一系列正在进行的缓解措施，包括：</p>
<ul>
<li>转变产品流动</li>
<li>供应商谈判和替代采购</li>
<li>成本削减和生产力提升，包括设施和后台效率</li>
</ul>
<p>投资者关系副总裁 Julie Winter 补充说，今年关税展望的增加主要是由于金属，并且由于组合的原因，资本设备销售的增加也增加了关税风险。关于 2027 财年，高管们表示，基于当前的关税，增量影响可能会有限，尽管他们指出关税率在年度内波动，特别是在上半年。</p>
<h2>前景和第四季度考虑</h2>
<p>STERIS 维持其 2026 财年指引，预计报告收入增长约 8%-9%，固定汇率有机收入增长 7%-8%。公司还重申调整后的每股收益指引为 10.15 美元至 10.30 美元，同时指出额外的关税降低了达到范围上限的可能性。自由现金流指引保持在 8.5 亿美元，资本支出保持在 3.75 亿美元。</p>
<p>在谈到对第四季度的预期时，Carestio 警告公司预计下半年将放缓，并指出与去年强劲的第四季度相比，特别是在 AST 方面的比较将非常艰难，去年资本设备表现强劲，而今年 “预计不会如此”。Winter 补充说，医疗保健服务的增长已经从早期水平放缓，并预计在第四季度继续放缓。</p>
<p>关于资本设备需求，Carestio 表示生命科学领域的订单积压改善反映了从制药客户支出减少的时期恢复过来，指出自去年第三季度以来订单预订有所增强。在医疗保健方面，他形容需求表现出韧性，引用了公司消毒和灭菌产品的必要性，并表示公司并未看到资本支出出现 “显著放缓”。</p>
<p>在讨论更广泛的市场因素时，Carestio 表示，手术程序向门诊手术中心的转移总体上对 STERIS 是积极的，提到新的产能需求和对灭菌和消毒的临床支持。他补充说，尽管他读到有关个人防护装备和活性药物成分制造的潜在转变，但尚未看到实质性影响。Carestio 还表示，公司仍致力于旨在实现更一体化商业模式的结构性变革，同时指出执行这些变革需要时间。</p>
<p>关于收购活动，Carestio 表示公司在较小的附加产品和渠道交易中保持活跃，但强调对大型交易采取谨慎的态度，指出 “重大变革性” 并购是困难的，必须满足财务标准和客户价值门槛。</p>
<h2>关于 STERIS NYSE: STE</h2>
<p>STERIS Corporation NYSE: STE 是一家全球提供感染预防、污染控制以及医疗保健、生命科学、制药和医疗设备行业程序产品和服务的公司。该公司开发、制造并支持广泛的设备和耗材组合，旨在降低感染风险、维持无菌环境并支持关键的临床和制造程序。</p>
<p>其产品包括灭菌和去污系统、仪器清洗机和清洗消毒机、内窥镜再处理解决方案、外科设备和一次性耗材，以及用于洁净室和实验室的污染控制产品。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 STERIS 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 STERIS 1,000 美元吗？</h2>
<p>在考虑 STERIS 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 STERIS 并不在名单上。</p>
<p>虽然 STERIS 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

标普健康医疗设备 ETF - SPDR

医药突破 ETF - ALPS

美国医药设备 ETF - iShares

<p>STERIS（纽约证券交易所代码：STE）在 2026 财年第三季度报告了广泛的增长，收入和每股收益均增长了 9%。尽管持续的关税压力和通货膨胀影响了盈利能力，公司仍维持全年指导。主要亮点包括来自持续运营的收入增长 9%，毛利率下降至 43.9%，自由现金流为 7.366 亿美元。医疗保健部门实现了 8% 的有机收入增长，而应用灭菌技术增长了 8%。STERIS 预计第四季度关税将增加，影响其每股收益指导</p>

<p>STERIS NYSE: STE executives highlighted broad-based third-quarter fiscal 2026 growth, improved earnings, and ongoing tariff headwinds during the company’s earnings call, while maintaining full-year guidance and pointing to a more challenging comparison in the fourth quarter.</p>
<div class="lb-trans"><p>STERIS NYSE: STE 的高管在公司财报电话会议上强调了 2026 财年第三季度的广泛增长、改善的盈利能力以及持续的关税压力，同时维持了全年指引，并指出第四季度的比较将更加具有挑战性。</p>
</div><h2>Third-quarter results: revenue up 9%, EPS up 9%</h2>
<div class="lb-trans"><h2>第三季度业绩：收入增长 9%，每股收益增长 9%</h2>
</div><p>Chief Financial Officer Karen Burton said third-quarter revenue from continuing operations rose 9% on an as-reported basis. Constant currency organic revenue increased 8%, driven by volume and about 200 basis points of price.</p>
<div class="lb-trans"><p>首席财务官 Karen Burton 表示，第三季度来自持续运营的收入按报告基准增长了 9%。在固定汇率下，按需收入增长了 8%，主要受销量和约 200 个基点的价格推动。</p>
</div><p>Profitability was pressured by tariffs and inflation. Gross margin declined 70 basis points year over year to 43.9%, with Burton noting that positive price and productivity benefits were “more than offset” by increased tariffs and inflation. EBIT margin decreased 40 basis points to 22.9% of revenue, which she said was mainly driven by the lower gross margin and partially mitigated by operating expense discipline.</p>
<div class="lb-trans"><p>盈利能力受到关税和通货膨胀的压力。毛利率同比下降 70 个基点至 43.9%，Burton 指出，积极的价格和生产力收益被增加的关税和通货膨胀 “完全抵消”。息税前利润（EBIT）率下降了 40 个基点，降至收入的 22.9%，她表示这主要是由于毛利率降低，部分通过运营费用的控制得以缓解。</p>
</div><p>The adjusted effective tax rate was 24.2%, down slightly from 24.5% a year earlier due primarily to changes in geographic mix. Adjusted net income from continuing operations was $249.4 million, and diluted EPS from continuing operations was $2.53, representing a 9% increase year over year.</p>
<div class="lb-trans"><p>调整后的有效税率为 24.2%，较去年同期的 24.5% 略有下降，主要由于地理组合的变化。来自持续运营的调整后净收入为 2.494 亿美元，稀释后每股收益为 2.53 美元，同比增长 9%。</p>
</div><h2>Cash flow, debt, and capital spending</h2>
<div class="lb-trans"><h2>现金流、债务和资本支出</h2>
</div><p>Burton said capital expenditures for the first nine months of fiscal 2026 totaled $278.8 million, while depreciation and amortization totaled $363.1 million. STERIS ended the quarter with $1.9 billion in total debt, and gross debt to EBITDA was approximately 1.2x.</p>
<div class="lb-trans"><p>Burton 表示，2026 财年前九个月的资本支出总计为 2.788 亿美元，而折旧和摊销总计为 3.631 亿美元。STERIS 在本季度结束时的总债务为 19 亿美元，毛债务与息税折旧摊销前利润（EBITDA）比率约为 1.2 倍。</p>
</div><p>Free cash flow for the first nine months of fiscal 2026 was $736.6 million, improving year over year due primarily to higher earnings and lower capital spending. In the Q&amp;A, management said it remained confident in its full-year free cash flow target but cited fourth-quarter timing factors—particularly a “heavy capital quarter”—that could shift cash collections into the next year. Burton also noted that winter weather can affect timing, contributing to a conservative stance on guidance.</p>
<div class="lb-trans"><p>2026 财年前九个月的自由现金流为 7.366 亿美元，同比改善，主要由于盈利能力提高和资本支出减少。在问答环节中，管理层表示对全年自由现金流目标保持信心，但提到第四季度的时机因素——特别是 “重资本季度”——可能会将现金回收推迟到明年。Burton 还指出，冬季天气可能会影响时机，导致对指引采取保守态度。</p>
</div><h2>Segment performance: Healthcare, AST, and Life Sciences</h2>
<div class="lb-trans"><h2>细分市场表现：医疗保健、AST 和生命科学</h2>
</div><p>President and CEO Dan Carestio said the company’s Healthcare segment delivered 8% constant currency organic revenue growth in the quarter, with “growth across all categories.” Service revenue continued to outperform, growing 11%, while consumables grew 8% and capital equipment rose 7%. Healthcare capital backlog remained above $400 million. Carestio said orders were down 1% year-to-date against “difficult comparisons” following a strong prior-year period.</p>
<div class="lb-trans"><p>总裁兼首席执行官 Dan Carestio 表示，公司医疗保健部门在本季度实现了 8% 的固定汇率有机收入增长，所有类别均有 “增长”。服务收入继续表现优异，增长 11%，而消耗品增长 8%，资本设备增长 7%。医疗保健资本积压保持在 4 亿美元以上。Carestio 表示，订单同比下降 1%，与去年强劲的业绩相比 “比较困难”。</p>
</div><p>Healthcare EBIT margin declined 100 basis points to 24.3%. Carestio attributed the margin decline to tariffs and inflation, which more than offset benefits from volume, pricing, and restructuring program initiatives.</p>
<div class="lb-trans"><p>医疗保健的 EBIT 率下降了 100 个基点，降至 24.3%。Carestio 将利润率下降归因于关税和通货膨胀，这些因素超过了销量、定价和重组计划带来的收益。</p>
</div><p>In Applied Sterilization Technologies (AST), constant currency organic revenue grew 8%, including 9% growth in services and 103% growth in capital equipment revenue. Carestio said AST services benefited from stable medical device volumes, bioprocessing demand, and currency. AST EBIT margin was 45.1%, up 30 basis points year over year, as pricing and volume more than offset higher labor and energy costs and an unfavorable mix impact from strong capital equipment growth.</p>
<div class="lb-trans"><p>在应用灭菌技术（AST）方面，固定汇率有机收入增长了 8%，其中服务增长 9%，资本设备收入增长 103%。Carestio 表示，AST 服务受益于稳定的医疗设备销量、生物处理需求和汇率。AST 的 EBIT 率为 45.1%，同比上升 30 个基点，因为定价和销量超过了更高的劳动力和能源成本以及强劲资本设备增长带来的不利组合影响。</p>
</div><p>In Life Sciences, constant currency organic revenue increased 5%, driven by 11% consumables growth. Capital equipment revenue increased 7%, and backlog remained above $100 million. Segment margins dipped 20 basis points, as volume and price gains were outweighed by tariffs and inflation.</p>
<div class="lb-trans"><p>在生命科学领域，固定汇率有机收入增长了 5%，主要受 11% 消耗品增长的推动。资本设备收入增长了 7%，积压保持在 1 亿美元以上。细分市场利润率下降了 20 个基点，因为销量和价格的增长被关税和通货膨胀所抵消。</p>
</div><h2>Tariffs: impact and mitigation efforts</h2>
<div class="lb-trans"><h2>关税：影响和缓解措施</h2>
</div><p>Carestio said third-quarter results included approximately $16 million of pre-tax tariff impact, primarily in the Healthcare segment. Management stated that tariff costs are expected to increase in the fourth quarter.</p>
<div class="lb-trans"><p>Carestio 表示，第三季度的业绩包括约 1600 万美元的税前关税影响，主要集中在医疗保健部门。管理层表示，预计第四季度的关税成本将增加。</p>
</div><p>During Q&amp;A, executives clarified that the $55 million tariff figure referenced in guidance reflects an annual run rate for fiscal 2026 and that tariffs have been incurred in every quarter. The company also indicated that the expected tariffs embedded in the full-year outlook increased by $10 million, which Carestio said makes the upper end of the EPS guidance range “less likely.”</p>
<div class="lb-trans"><p>在问答环节中，高管们澄清了指引中提到的 5500 万美元关税数字反映的是 2026 财年的年化运行率，并且每个季度都产生了关税。公司还表示，全年展望中预期的关税增加了 1000 万美元，Carestio 表示这使得每股收益指引范围的上限 “变得不太可能”。</p>
</div><p>Management described a broad set of mitigation actions underway, including:</p>
<div class="lb-trans"><p>管理层描述了一系列正在进行的缓解措施，包括：</p>
</div><ul>
<li>Shifting product movement</li>
<li>Supplier negotiations and alternative sourcing</li>
<li>Cost reductions and productivity improvements, including facility and back-office efficiencies</li>
</ul>
<div class="lb-trans"><ul>
<li>转变产品流动</li>
<li>供应商谈判和替代采购</li>
<li>成本削减和生产力提升，包括设施和后台效率</li>
</ul>
</div><p>Investor Relations Vice President Julie Winter added that the increase in the year’s tariff outlook is mainly driven by metals and that higher capital equipment sales increase tariff exposure due to mix. On fiscal 2027, executives suggested that, based on current tariffs, incremental impact would likely be limited, though they noted tariff rates fluctuated during the year, particularly in the first half.</p>
<div class="lb-trans"><p>投资者关系副总裁 Julie Winter 补充说，今年关税展望的增加主要是由于金属，并且由于组合的原因，资本设备销售的增加也增加了关税风险。关于 2027 财年，高管们表示，基于当前的关税，增量影响可能会有限，尽管他们指出关税率在年度内波动，特别是在上半年。</p>
</div><h2>Outlook and Q4 considerations</h2>
<div class="lb-trans"><h2>前景和第四季度考虑</h2>
</div><p>STERIS maintained its fiscal 2026 guidance, calling for approximately 8%–9% as-reported revenue growth and 7%–8% constant currency organic revenue growth. The company also reiterated adjusted EPS guidance of $10.15 to $10.30, while noting that additional tariffs reduce the likelihood of reaching the high end of the range. Free cash flow guidance remains $850 million, and CapEx remains $375 million.</p>
<div class="lb-trans"><p>STERIS 维持其 2026 财年指引，预计报告收入增长约 8%-9%，固定汇率有机收入增长 7%-8%。公司还重申调整后的每股收益指引为 10.15 美元至 10.30 美元，同时指出额外的关税降低了达到范围上限的可能性。自由现金流指引保持在 8.5 亿美元，资本支出保持在 3.75 亿美元。</p>
</div><p>Addressing expectations for the fourth quarter, Carestio cautioned that the company anticipated a slowdown in the second half and pointed to a tough comparison versus a strong prior-year fourth quarter, particularly in AST, where capital equipment performance was strong last year and is “not expected this year.” Winter added that Healthcare services growth has already decelerated from earlier levels and is expected to continue slowing in the fourth quarter.</p>
<div class="lb-trans"><p>在谈到对第四季度的预期时，Carestio 警告公司预计下半年将放缓，并指出与去年强劲的第四季度相比，特别是在 AST 方面的比较将非常艰难，去年资本设备表现强劲，而今年 “预计不会如此”。Winter 补充说，医疗保健服务的增长已经从早期水平放缓，并预计在第四季度继续放缓。</p>
</div><p>On capital equipment demand, Carestio said Life Sciences backlog improvement reflects a recovery from a period when pharmaceutical customers were spending less, noting stronger order bookings beginning in the prior year’s third quarter. In Healthcare, he described demand as resilient, citing the essential nature of the company’s sterilization and disinfection offerings and stating that the company has not seen a “meaningful slowdown” in capital spending.</p>
<div class="lb-trans"><p>关于资本设备需求，Carestio 表示生命科学领域的订单积压改善反映了从制药客户支出减少的时期恢复过来，指出自去年第三季度以来订单预订有所增强。在医疗保健方面，他形容需求表现出韧性，引用了公司消毒和灭菌产品的必要性，并表示公司并未看到资本支出出现 “显著放缓”。</p>
</div><p>In discussing broader market factors, Carestio said the shift of procedures toward ambulatory surgery centers has generally been positive for STERIS, citing new capacity needs and the clinical support required for sterilization and disinfection. He added that while he has read about potential shifts related to PPE and active pharmaceutical ingredient manufacturing, he has not yet seen material impacts. Carestio also said the company remains committed to structural changes aimed at a more integrated commercial approach in EMEA, while noting it will take time to execute.</p>
<div class="lb-trans"><p>在讨论更广泛的市场因素时，Carestio 表示，手术程序向门诊手术中心的转移总体上对 STERIS 是积极的，提到新的产能需求和对灭菌和消毒的临床支持。他补充说，尽管他读到有关个人防护装备和活性药物成分制造的潜在转变，但尚未看到实质性影响。Carestio 还表示，公司仍致力于旨在实现更一体化商业模式的结构性变革，同时指出执行这些变革需要时间。</p>
</div><p>On acquisition activity, Carestio said the company has remained active in smaller bolt-on product and channel deals but emphasized a disciplined approach to larger transactions, noting that “major transformative” M&amp;A is difficult and must meet financial criteria and customer value thresholds.</p>
<div class="lb-trans"><p>关于收购活动，Carestio 表示公司在较小的附加产品和渠道交易中保持活跃，但强调对大型交易采取谨慎的态度，指出 “重大变革性” 并购是困难的，必须满足财务标准和客户价值门槛。</p>
</div><h2>About STERIS NYSE: STE</h2>
<div class="lb-trans"><h2>关于 STERIS NYSE: STE</h2>
</div><p>STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.</p>
<div class="lb-trans"><p>STERIS Corporation NYSE: STE 是一家全球提供感染预防、污染控制以及医疗保健、生命科学、制药和医疗设备行业程序产品和服务的公司。该公司开发、制造并支持广泛的设备和耗材组合，旨在降低感染风险、维持无菌环境并支持关键的临床和制造程序。</p>
</div><p>Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.</p>
<div class="lb-trans"><p>其产品包括灭菌和去污系统、仪器清洗机和清洗消毒机、内窥镜再处理解决方案、外科设备和一次性耗材，以及用于洁净室和实验室的污染控制产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than STERIS</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 STERIS 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in STERIS Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 STERIS 1,000 美元吗？</h2>
</div><p>Before you consider STERIS, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 STERIS 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 STERIS 并不在名单上。</p>
</div><p>While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 STERIS 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

STERIS 第三季度财报电话会议亮点